nitisinone dipharma 2 mg hard caps.
dipharma arzneimittel gmbh - nitisinone 2 mg - capsule, hard - 2 mg - nitisinone 2 mg - nitisinone
nitisinone dipharma 20 mg hard caps.
dipharma arzneimittel gmbh - nitisinone 20 mg - capsule, hard - 20 mg - nitisinone 20 mg - nitisinone
orfadin nitisinone 4 mg/ml oral suspension bottle
a menarini australia pty ltd - nitisinone, quantity: 4 mg - oral liquid, suspension - excipient ingredients: hypromellose; glycerol; polysorbate 80; sodium benzoate; citric acid monohydrate; sodium citrate; purified water; flavour - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.
orfadin nitisinone 20 mg capsule bottle
a menarini australia pty ltd - nitisinone, quantity: 20 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.
highlights of prescribing information
novitium pharma llc - nitisinone (unii: k5bn214699) (nitisinone - unii:k5bn214699) - nitisinone capsules are indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine. none. risk summary limited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. animal reproduction studies have been conducted for nitisinone. in these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended initial dose of 1 mg/kg/day. in mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended initial dose, and increased gestational length at doses 4 times the recommended initial dose. in rabbits, nitisinone caused maternal toxicity and incomplete skeletal ossification of fetal bones at doses 1.6 times the recommended initial dose [see data]. the b
nitisinone dipharma 10 mg
mbi pharma ltd., israel - nitisinone - hard capsule - nitisinone 10 mg - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
nitisinone dipharma 5 mg
mbi pharma ltd., israel - nitisinone - hard capsule - nitisinone 5 mg - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
orfadin 2 mg hard capsules
megapharm ltd - nitisinone - hard capsule - nitisinone 2 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine05/06/2018 בקשה לשינוי משטר מינון once daily
orfadin 5 mg hard capsules
megapharm ltd - nitisinone - hard capsule - nitisinone 5 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine05/06/2018 בקשה לשינוי משטר מינון once daily
orfadin 10 mg hard capsules
megapharm ltd - nitisinone - hard capsule - nitisinone 10 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine05/06/2018 בקשה לשינוי משטר מינון once daily